Fibrosarcoma is a rare malignant tumor that arises from fibroblasts, the cells responsible for producing connective tissue throughout the body. It was once considered the most common sarcoma in adults, but that distinction has largely evaporated as pathologists got better at telling it apart from tumors that merely resemble it. Today, adult-type fibrosarcoma is essentially a diagnosis of exclusion, given only after other look-alikes have been ruled out. The story of fibrosarcoma is as much about how cancer classification has evolved as it is about the tumor itself, and the infantile form of the disease has become one of the more encouraging success stories in precision oncology.
From the Most Common Sarcoma to a Rarity
For much of the twentieth century, fibrosarcoma sat at the top of the soft tissue sarcoma list. That changed dramatically over several decades for three overlapping reasons: the classification system for soft tissue tumors evolved, pathologists identified distinct subtypes that had been lumped under the fibrosarcoma umbrella, and researchers came to understand that many tumors mimicking fibrosarcoma were actually entirely different entities with their own biology and behavior.1PubMed. Fibrosarcoma: a review and update A landmark re-examination of 163 cases originally diagnosed as adult fibrosarcoma at a single institution over nearly five decades found that the label had been applied so broadly that, under modern criteria, many of those tumors would be reclassified as something else entirely.2The American Journal of Surgical Pathology. Adult-type Fibrosarcoma: A Reevaluation of 163 Putative Cases Diagnosed at a Single Institution Over a 48-year Period
The practical upshot is that when a pathologist today diagnoses adult-type fibrosarcoma, they have already ruled out synovial sarcoma, malignant peripheral nerve sheath tumor, dedifferentiated liposarcoma, and a host of other spindle-cell neoplasms that share a superficial resemblance. Immunohistochemistry panels using markers like CD34, desmin, S100 protein, and keratin cocktails help distinguish fibroblastic tumors from myoid, nerve sheath, and epithelioid sarcomas that would otherwise look similar under the microscope.3PubMed Central. Immunohistochemistry of soft tissue tumours – review with emphasis on 10 markers This rigorous exclusion process means the diagnosis is genuinely rare now, not because fewer people develop it but because what once carried the label was never one disease.
Adult Versus Infantile Fibrosarcoma
The distinction between adult and infantile fibrosarcoma is not just a matter of age. These are biologically different diseases with different microscopic appearances, different genetic drivers, and very different outcomes.
Adult fibrosarcoma occurs mostly in people between their mid-twenties and late sixties. Under the microscope, it consists of spindle-shaped fibroblastic cells arranged in interlacing bundles, often accompanied by varying amounts of collagen.4PubMed. Infantile and adult fibrosarcomas of the soft tissues The so-called “herringbone pattern,” in which hyperchromatic spindle cells form fascicles set against a collagen background, is the classic histologic hallmark that pathologists look for.5PubMed Central. Fibrosarcoma: Origin, differential diagnosis, and report of a case in the mandible The malignant fibroblasts also remodel the surrounding extracellular matrix in ways that help the tumor grow, survive, and invade neighboring tissue.6PubMed. Could growth factor-mediated extracellular matrix deposition and degradation offer the ground for directed pharmacological targeting in fibrosarcoma?
Infantile fibrosarcoma (also called congenital fibrosarcoma when present at birth) affects children under about seven years of age. Its cells are more immature, form less distinct bundles, and the tumor often contains areas that look like abnormal blood vessels.7PubMed. Infantile and adult fibrosarcomas of the soft tissues Despite its aggressive-looking microscopic features, infantile fibrosarcoma has a considerably better prognosis than the adult form, in large part because of a specific genetic abnormality that now doubles as a therapeutic target.
The ETV6-NTRK3 Fusion and Why It Matters
The defining genetic event in congenital and infantile fibrosarcoma is a chromosomal rearrangement that fuses two genes: ETV6 on chromosome 12 and NTRK3 on chromosome 15. This fusion was first identified in the late 1990s and was found in all congenital fibrosarcoma tumors analyzed in the original report.8PubMed. A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma The resulting protein acts as a constantly active growth signal, essentially telling the cell to keep dividing.
This discovery turned out to be far more than an academic curiosity. The NTRK3 gene encodes a tropomyosin receptor kinase (TRK), and within the past decade, drugs designed to block TRK signaling have transformed the treatment landscape for these children. Larotrectinib, the first TRK inhibitor approved for clinical use, has shown remarkable results. In a pooled analysis of 91 pediatric patients with TRK fusion sarcomas across two clinical trials, the overall response rate was about 87%. Nearly half of the cohort had infantile fibrosarcoma specifically.9PubMed Central. Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal Tumors
Individual case reports illustrate just how dramatic the responses can be. One infant with recurrent fibrosarcoma that had not responded to chemotherapy achieved a complete response by day 56 of larotrectinib treatment, with the tumor essentially disappearing on imaging. The remission was sustained for over 16 months with negligible side effects.10PubMed Central. Rapid, complete and sustained tumour response to the TRK inhibitor larotrectinib in an infant with recurrent, chemotherapy-refractory infantile fibrosarcoma carrying the characteristic ETV6-NTRK3 gene fusion In another series, three children with locally invasive infantile fibrosarcoma all achieved complete responses, and two were spared amputations they would otherwise have needed.11The Turkish Journal of Pediatrics. Three locally invasive infantile fibrosarcoma cases treated with larotrectinib
For a tumor that used to require mutilating surgery or aggressive chemotherapy, these outcomes represent a genuine shift. TRK inhibitors offer a way to shrink the tumor before surgery or, in some cases, avoid radical surgery altogether. The adult form of fibrosarcoma does not carry this fusion gene and does not respond to TRK inhibitors, which underscores why the adult-versus-infantile distinction has real clinical consequences.
Where Adult Fibrosarcoma Tends to Appear
Adult fibrosarcoma favors the extremities, particularly the lower limbs. In one imaging study of ten confirmed cases, five were in the hip area, two in the legs, and one each in the popliteal fossa (behind the knee), the foot, and the arm. The tumors were usually lobulated, deep-seated along the fascia, and their long axes tended to run parallel to the limb. The average diameter was close to 7 cm, though individual tumors ranged from just over 1 cm to more than 10 cm. Borders were generally well defined, and bone destruction was uncommon but not impossible.12PubMed Central. CT and MRI Findings of Soft Tissue Adult Fibrosarcoma in Extremities
In practice, most patients notice a painless or mildly tender mass that has been growing for weeks to months. Because the tumor sits deep to the skin, it can reach a significant size before anyone feels it. That delay is one of the challenges with soft tissue sarcomas generally: there is no reliable screening tool, and the initial lump can be mistaken for a benign cyst or lipoma.
Surgery and the Margin Question
Wide surgical excision is the primary treatment for adult fibrosarcoma and its close relative myxofibrosarcoma. Getting clean margins, meaning no tumor cells at the edge of the resected tissue, is consistently linked to better outcomes. Research on myxofibrosarcoma, a closely related tumor that shares many clinical features with classic fibrosarcoma, provides much of the data here. In one series, only about 13% of patients with clear surgical margins developed a local recurrence, compared with 86% of patients whose margins were positive.13PubMed. A clinicopathologic examination of myxofibrosarcoma. Do surgical margins significantly affect local recurrence rates in this infiltrative sarcoma subtype?
How wide the margin needs to be is harder to pin down. One study found that margins greater than 1 mm appeared to be associated with lower recurrence rates and better overall survival, which sounds razor-thin but reflects the biological reality that these tumors infiltrate tissue along fascial planes in ways that are difficult to predict from imaging alone.14PubMed Central. Is the Thickness of the Margin Associated With Local Recurrence and Survival in Patients With Myxofibrosarcoma? Another analysis confirmed that the specific width of the negative margin was less important than whether any tumor was left behind: having residual tumor at the resection edge, whether visible to the surgeon or detected only on microscopy, was the factor that drove recurrence risk upward.15Scientific Reports. Impact of resection margins on local recurrence in patients with myxofibrosarcoma
The bottom line for surgeons, then, is less about achieving a specific centimeter measurement and more about making sure the final pathology report shows no tumor at the cut edge. When the tumor involves a limb, the surgical team weighs wide excision against limb preservation, and reconstructive procedures such as soft tissue flaps are sometimes needed to close the defect.
Chemotherapy in Advanced Disease
Standard chemotherapy for advanced fibrosarcoma and myxofibrosarcoma relies on the same backbone used in many soft tissue sarcomas: anthracycline-based regimens, often combined with ifosfamide. The results are modest. In a series of patients with advanced myxofibrosarcoma, front-line combination chemotherapy produced partial responses in roughly a third of patients, but the median time before the disease progressed was only about four months. Even high-dose ifosfamide as a second-line option yielded a similar progression-free survival, and median overall survival for the group was about a year.16PubMed Central. Activity of anthracycline- and ifosfamide-based chemotherapy in a series of patients affected by advanced myxofibrosarcoma
These numbers are humbling but consistent with what oncologists see across most soft tissue sarcoma subtypes: chemotherapy can buy time and occasionally shrink tumors enough to make surgery feasible, but durable responses in advanced disease are rare with conventional agents. This reality makes the TRK-inhibitor results in infantile fibrosarcoma all the more striking by comparison.
What Drives Prognosis
A large analysis of fibrosarcoma cases drawn from a national cancer database identified several factors that independently predicted how long patients survived: age at diagnosis, tumor stage, pathologic grade, tumor size, and whether surgery was performed.17PubMed Central. Nomograms Predict Overall Survival and Cancer-Specific Survival in Patients with Fibrosarcoma: A SEER-Based Study Younger patients, smaller tumors, lower-grade tumors, and earlier-stage disease all carried better odds.
When fibrosarcoma does spread, the lungs are the most common destination for distant metastasis.18MEDALION Journal: Medical Research, Nursing, Health and Midwife Participation. PULMONARY METASTASES FROM FIBROSARCOMA: A CASE REPORT Pulmonary metastases can sometimes be resected surgically if they are few in number and confined to one area, but widespread lung disease at the time of diagnosis generally signals a poor outcome.
Radiation-Associated and Secondary Fibrosarcoma
One of the known causes of fibrosarcoma is prior radiation therapy. Secondary sarcomas can develop in the radiation field years or even decades after treatment for another cancer, though case reports have documented them appearing within just a couple of years. When a new mass shows up in a previously irradiated area, clinicians are advised to consider the possibility of sarcoma even if the timing seems early.19PubMed. An unusual case of secondary fibrosarcoma after treatment for breast cancer Radiation-associated sarcomas in general tend to have complex chromosomal abnormalities with multiple structural rearrangements, a pattern broadly similar to their non-radiation-associated counterparts but sometimes more chaotic.
The Tumor’s Relationship with Its Surroundings
Fibrosarcoma does not just grow in isolation. The cells actively remodel their extracellular environment, altering the composition and organization of the connective-tissue matrix around them to create conditions favorable for invasion and survival.20PubMed. Could growth factor-mediated extracellular matrix deposition and degradation offer the ground for directed pharmacological targeting in fibrosarcoma? Research using fibrosarcoma cell lines in animal models has shown that a matrix molecule called versican, produced by the host’s own stromal cells, plays a surprisingly protective role: when host-derived versican is absent, tumors actually proliferate faster, blood vessel formation increases, and the normal cancer-restraining functions of surrounding fibroblasts break down.21PubMed. Host stromal versican is essential for cancer-associated fibroblast function to inhibit cancer growth
This finding is counterintuitive. The body’s own connective-tissue scaffold can actually slow down tumor growth, and the tumor’s efforts to dismantle and remodel that scaffold serve its expansion. Understanding this interplay is part of a broader effort to find drug targets beyond the tumor cells themselves, though no therapies targeting the fibrosarcoma matrix have yet reached routine clinical use.
Life After Limb-Salvage Surgery
For patients with extremity fibrosarcoma who undergo limb-salvage surgery, the physical aftermath can be significant. A report on patients who received expandable prosthetic reconstructions found that physical function scores lagged behind national averages even roughly two and a half years after surgery. Pain levels were generally low, and emotional acceptance of the situation was high, but patients continued to struggle with walking speed, stride length, and the ability to perform everyday movements smoothly. Many developed compensatory weight-bearing strategies, relying more heavily on the non-operated limb.22PubMed. Functional outcomes after limb-salvage surgery and endoprosthetic reconstruction with an expandable prosthesis: a report of 4 cases
When soft tissue flap reconstruction is needed to close surgical wounds, early studies suggested that patients scored slightly lower on functional outcome measures in the short term. However, on closer analysis accounting for the complexity of their cases, the flap reconstruction itself did not independently predict worse long-term function or health status.23PubMed. Function and health status outcomes following soft tissue reconstruction for limb preservation in extremity soft tissue sarcoma In other words, patients who need flap reconstruction tend to have bigger or more complex tumors, and the complexity of the tumor drives the outcome more than the complexity of the repair.
Fibrosarcoma in Cats
Fibrosarcoma is not exclusively a human disease, and one of the more unusual chapters in its story involves domestic cats. Feline injection-site sarcomas, the majority of which are fibrosarcomas, can develop at locations where cats have received vaccinations or other injections. The prevailing theory is that chronic inflammation triggered by certain vaccine adjuvants or long-acting injectable drugs sets the stage for malignant transformation over time.24PubMed Central. Feline injection-site sarcoma Insoluble aluminum compounds used as adjuvants, and even implanted microchips, have been implicated as potential foreign-body triggers that provoke sustained inflammation, DNA damage, and eventually tumor formation.25PubMed Central. Origins of Injection-Site Sarcomas in Cats: The Possible Role of Chronic Inflammation—A Review
These feline tumors are locally aggressive and have high recurrence rates after surgery alone. A study of 33 cats with histologically confirmed fibrosarcomas treated with radiation therapy followed by surgery reported a median disease-free interval of about 398 days and overall survival of roughly 600 days.26PubMed. Radiation therapy and surgery for fibrosarcoma in 33 cats The feline experience has actually fed back into human oncology thinking, because injection-site sarcomas in cats serve as a natural model for how chronic inflammation can drive sarcoma development, a mechanism that parallels what happens in radiation-associated sarcomas in people. Veterinary guidelines now recommend administering vaccines in the distal limbs rather than between the shoulder blades, so that if a sarcoma does develop, amputation is at least surgically feasible.